Purpose
The purpose of the Academy of Translational Medicine Platform is to accelerate the translation of innovative healthcare assets, providing guidance and evidence on implementation, regulatory, and evidence strategy and strategic asset valuation.
Eligibility and Scope
UBC inventors and sponsors including students, postdoctoral fellows, faculty, and staff are eligible to apply for consideration for the ATM Platform.
Eligible health innovation assets include therapeutics, devices, diagnostics, and software.
The Intake Process
Sponsors (Investigators) must first submit their candidate asset for consideration by the ATM Intake Group (ATM/IG) by filling out the ATM Platform Intake Form and evidence summary tool.
The ATM/IG then evaluates candidate assets on a rolling basis utilizing the ATM Prioritization Framework. The framework is designed to facilitate a deliberation process that simultaneously considers, scores, weights, and ranks candidate assets across five evidence categories:
- Equity and access (priority populations, accessibility)
- Unmet medical need (incidence, prevalence, survival, severity, urgency, gaps in care)
- Healthcare cost (healthcare cost of condition, price of competing products)
- Product innovation (competing products available, macroeconomic benefit, marketability, uncertainty in evidence
- base)
- Technology readiness level (TRL) (TRL 1-9, biomanufacturing feasibility)
The result of the deliberation will guide prioritization regarding which assets gain access to the ATM Platform. It is important to fill out all areas of the intake form and evidence summary tool to the best of your ability. Missing or incomplete responses may limit the ATM/IG’s ability to accurately evaluate your proposal.
The ATM is committed to keeping all information disclosed within the candidate asset intake process confidential.
Access the intake form here.
